When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Transtorno depressivo persistente

Last reviewed: 13 Jan 2026
Last updated: 25 Jul 2023

Summary

Definition

History and exam

Key diagnostic factors

  • transtorno de humor crônico que dura mais de 2 anos
  • sintomas depressivos presentes na maior parte do dia, quase todos os dias
  • nenhum período de eutimia nos últimos 2 anos (1 ano para crianças ou adolescentes)
  • os sintomas de depressão maior podem estar constantemente presentes por 2 anos ou mais
Full details

Other diagnostic factors

  • nenhum sintoma de mania/hipomania ou esquizofrenia
  • ausência de quadros médicos subjacentes, uso de medicamentos ou abuso de substâncias que possam causar o transtorno de humor
  • fadiga ou baixa energia
  • baixa autoestima
  • baixa concentração ou dificuldade para tomar decisões
  • sentimentos de desesperança
  • inapetência ou ingestão excessiva de alimentos
  • perturbação do sono
Full details

Risk factors

  • história familiar positiva
  • sexo feminino
Full details

Diagnostic tests

1st tests to order

  • avaliação médica
  • Hemograma completo
  • testes da função tireoidiana
  • perfil metabólico
  • vitamina D
  • Questionário sobre a saúde do(a) paciente (PHQ9)
  • Inventário de Depressão de Beck (BDI)
  • Inventário rápido de sintomas depressivos (QIDS)
Full details

Tests to consider

  • cianocobalamina (vitamina B12)
  • exame de urina
  • eletrocardiograma (ECG)
Full details

Treatment algorithm

ACUTE

todos os pacientes

Contributors

Authors

David J. Hellerstein, MD
David J. Hellerstein

Professor of Clinical Psychiatry

Columbia University Medical Center

Director, Depression Evaluation Service

New York State Psychiatric Institute

New York

NY

Disclosures

DJH has received research grants (through the Research Foundation for Mental Hygiene) from Compass Pathways, Relmada, Marinus, Intracellular Therapies, Beckley Foundation, and from Velocity Foundation (through Columbia University). DJH serves on scientific advisory board for Reset Pharmaceuticals. DJH has received royalties from Johns Hopkins University Press, and Columbia University Press.

Acknowledgements

Dr David J. Hellerstein would like to gratefully acknowledge Dr David L. Dunner, a previous contributor to this topic.

Disclosures

DLD has received grant support from Cyberonics. DLD has received fees for consulting from: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Forest, Cyberonics, Roche Diagnostics, Cypress, Corcept, Janssen, Novartis, Shire, Somerset, Otsuka, Healthcare Technology Sys, Jazz Pharma, Sanofi-Aventis, and MedAvante. DLD is on the Speaker's Bureau for: Eli Lilly, Pfizer, GlaxoSmithKline, Wyeth, Bristol-Myers Squibb, Organon, Jazz Pharma, Neuronetics, and Astra-Zeneca. DLD is an author of several references cited in this topic.

Peer reviewers

Dean F. MacKinnon, MD

Associate Professor

John Hopkins University

Baltimore

MD

Disclosures

DK declares that he has no competing interests.

James H. Kocsis, MD

Professor

Weill Cornell Medicine

New York

NY

Declarações

JK has professionally collaborated with the authors.

Neil Nixon, BSc, MMedSci, MBBS, FRCPsych

Associate Professor in Psychiatry

Institute of Mental Health

University of Nottingham

Nottingham

UK

Declarações

NN is a member of the current NICE GDG for depression in adults. NN has met with Jansen in a non-remunerative capacity. He has various research collaborations including a funded trial and is author on a number of papers.

Créditos aos pareceristas

Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.

Declarações

As afiliações e declarações dos pareceristas referem--se ao momento da revisão.

Referências

Nossas equipes internas de editoria e de evidências trabalham em conjunto com colaboradores internacionais especializados e pares revisores para garantir que forneçamos acesso às informações o mais clinicamente relevantes possível.

Principais artigos

American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

Blanco C, Okuda M, Markowitz JC, et al. The epidemiology of chronic major depressive disorder and dysthymic disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2010 Dec;71(12):1645-56.Texto completo  Resumo

Devanand DP, Adorno E, Cheng J, et al. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord. 2004 Mar;78(3):259-67. Resumo

Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. J Clin Psych. 2011 Apr;72(4):509-14. Resumo

Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007 Apr 18;297(15):1683-96. Resumo

Pedrelli P, Iovieno N, Vitali M, et al. Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis. J Clin Psychopharmacol. 2011 Oct;31(5):582-6. Resumo

Bauer M, Severus E, Köhler S, et al; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 2: maintenance treatment of major depressive disorder - update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95.Texto completo  Resumo

Artigos de referência

Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.
  • Differentials

    • Transtorno depressivo maior
    • Transtornos bipolares (bipolar I, bipolar II, transtorno bipolar sem outra especificação)
    • Transtorno ciclotímico
    More Differentials
  • Guidelines

    • Depression in adults: treatment and management
    • Clinical practice guideline for the assessment and treatment of children and adolescents with major and persistent depressive disorders
    More Guidelines
  • Patient information

    Depressão em crianças e adolescentes: perguntas para fazer ao seu médico

    Depressão em adultos: quais são as opções de tratamento?

    More Patient information
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer